Directors Deals 

Abcam deputy chairman offloads shares

Abcam deputy chairman offloads shares

Expansion plans from life sciences company Abcam (ABC) have not been met with a warm welcome from investors. Management is planning to spend between £175m and £225m between now and 2024 on growth initiatives, including further antibody innovation and expansion into adjacent life sciences markets. In doing so it’s hoping to nearly double its revenue to £450m-£500m over the next five years, but this will come at the expense of the adjusted cash profit margin, expected to be squeezed from 35.6 per cent to 32-35 per cent in FY2020.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now